Evotec has partnered Bristol-Myers Squibb to launch another Bridge programme, this time focusing on the universities of Birmingham, Dundee, Edinburgh and Nottingham.

The universities of Birmingham, Dundee, Edinburgh and Nottingham have joined forces with drug discovery firm Evotec and pharmaceutical firm Bristol-Myers Squibb to launch BeLab1407. Equipped with $20m, BeLab1407 is the latest addition to Evotec’s international network of early-stage academic collaborations called Bridge – an acronym for Biomedical Research, Innovation and Development Generation Efficiency. It will…

The rest of this content is only accessible to Global Venturing Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.